Such molecules that are evaluated in trials include aflibercept, a recombinant fusion protein which is a potent inhibitor of VEGF (known as VEGF trap) and of placental growth factor and vatalanib, a small molecule TKI targeting selectively VEGF Receptors 1, 2, and 3

Such molecules that are evaluated in trials include aflibercept, a recombinant fusion protein which is a potent inhibitor of VEGF (known as VEGF trap) and of placental growth factor and vatalanib, a small molecule TKI targeting selectively VEGF Receptors 1, 2, and 3. Additionally, molecules with broad spectrum of activity are available and enriching our options for clinical trials in order to identify the most effective and less toxic combination. both more urgent and promising. The aim of this review was to summarize the molecular basis of pancreatic carcinogenesis and the latest developments in diagnosis by molecular means, focusing on the results of clinical research into targeted and personalized treatments. Keywords:Pancreatic ductal carcinoma, Molecular targets, Pharmacogenetics, Novel brokers == INTRODUCTION == Pancreatic cancer (PC) is the 4th commonest cause of cancer related deaths according to statistics for 2008 by the American Cancer Society. The mortality rate of pancreatic cancer is very high (99%) and the 5-year survival rate for all those stages equal or less to 5%. The incidence of this lethal disease is usually fortunately much lower, representing only 2% of all cancers (10th commonest cause) in United States and rather the same in the rest of western world. There are few risk factors that have been identified in the sporadic form of pancreatic cancer which accounts for the 90% of all cases (genetic syndromes are accountable for the rest 10%). Such risk factors are cigarette smoking, age >55 years, obesity, lack of exercise, male gender and possibly but less certainly chronic pancreatitis and diabetes type II.1The fact that most of the above factors have showed an increasing tendency during the Triptophenolide last decades may explain why the mortality rate is not slowing down despite improvements in treatment. The gold standard treatment for early stage pancreatic cancer is radical surgery (Whipple’s operation) which is actually the sole curative option in this aggressive tumor. Chemotherapy can be used as adjuvant to surgery or in advanced stage pancreatic cancer where, in a small group of patients, it offers real benefit in terms of survival and quality of life. In addition, radiotherapy may offer in selected cases local control in advanced nonmetastatic disease when surgery is either not feasible or incomplete. Due to poor results of the conventional treatments, a labor effort in translational science is taking place over the last decade aiming to an earlier Triptophenolide diagnosis and a more effective treatment. Below, we will focus on the aberrant biological pathways involved in the pathogenesis of pancreatic cancer and the deranged molecules or genes that are attracting diagnostic or therapeutic interest. Finally, we will present the current status of novel treatments produced in drug development units which may allow applying a more rational patient’s management. == GENETIC AND MOLECULAR BACKGROUND OF PANCREATIC CANCER == There are many different histological subtypes of pancreatic cancer, with variable natural history, management and outcome. Pancreatic Triptophenolide ductal adenocarcinoma (PDAC) is the commonest subtype followed by cystic neoplasms (serous cystadenocarcinoma, intraductal papillary mucinous neoplasm-IPMN), neuroendocrine tumors, sarcoma, acinar cell carcinoma and lymphoma. Though there is evidence that PDAC may also develop on the background of mucinous neoplasms (IPMN or mucinous cystic), we will not deal with the molecular aspects of those rather rare cases in this review. In the majority of published works, the term pancreatic cancer refers exclusively to PDAC. The carcinogenesis of pancreatic neoplasms entails transformation of a normal cell to a benign or premalignant cell, as those seen in pancreatic intraepithelial neoplasia (PanIN). Various genetic mutations, progressive nuclear alterations, such as increasing atypia and loss of polarity, as well as morphological cellular changes do occur and mount up during the malignant process from the early PanIN1to the more advanced DDIT4 PanIN3 or carcinomain situand finally pancreatic cancer.2,3 Therefore, the observed genetic mutations in this disease involve the oncogenesKRASin the majority of cases (74-100%),HER-2/neu(in about 65%),notch1,Akt-2andCOX-2, and the tumor suppressor genesp16INK4a(in up to 98%),p53(43 to 76%),DPC4(about 50%),FHIT(found in 70% of cases) andBRCA2in familial cases.4-10 Apart from single genetic changes there are specific chromosomal abnormalities involved in pancreatic carcinogenesis. Thus, we may see allelic loss Triptophenolide mainly in chromosomes 17p (95%), 18q (88%), 9p (76%), 12q (67%) and less often in 1p, 6p, 6q, 8p, 10p, 10q, 12p, 21q, and 22q (from 50% to 60%). There are.